ICHNO-ECHNO 2022 - Abstract Book

S4

ICHNO-ECHNO 2022

Conclusion Unbiased global metabolomics profiling is a promising strategy in the discovery of biomarkers. Our present work shows that there are significant differences in the metabolome of individuals that do not respond to radiotherapy. More work is underway to validate these initial test set results and to identify the metabolites that could lead to a metabolic signature able to detect radio-resistant tumours.

OC-0009 Real-life data on the lenvatinib activity in relapsed/metastatic adenoid cystic carcinoma of salivary glands.

F. Caspani 1 , S. Cavalieri 2 , E. Orlandi 3 , C. Bergamini 2 , C. Resteghini 4 , E. Colombo 4 , A. Ottini 4 , I. Nuzzolese 4 , S. Alfieri 5 , A. Mirabile 6 , A. Cassano 7 , P. Bossi 8 , T. Ibrahim 9 , M. Ghiani 10 , F. Bertolini 11 , R. Ingargiola 12 , L. Licitra 4 , L. Locati 13 1 IRCCS Istituto Nazionale dei Tumori, Head and Neck Medical oncology, Milano, Italy; 2 IRCCS Istituto Nazionale dei Tumori, Head and Neck Medical Oncology, Milan, Italy; 3 Fondazione CNAO - Centro Nazionale di Adroterapia Oncologica, Radiotherapy, Pavia, Italy; 4 IRCCS Istituto Nazionale dei Tumori , Head and Neck Medical Oncology, Milan, Italy; 5 CRO IRCCS, Head and neck medical oncology, Aviano, Italy; 6 San Raffaele Hospital, Medical Oncology, Milan, Italy; 7 Gemelli Hospital, Medical Oncology, Rome, Italy; 8 ASST Spedali Civili , Medical Oncology, Brescia, Italy; 9 Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori , Medical Oncology, Meldola, Italy; 10 Ospedale Oncologico Businco , Medical Oncology, Cagliari, Italy; 11 Azienda Ospedaliera - Universitaria di Modena , Medical Oncology, Modena, Italy; 12 Fondazione CNAO - Centro Nazionale di Adroterapia Oncologica , Radiotherapy, Pavia, Italy; 13 IRCCS Istituto Nazionale dei Tumori , Head and Neck Medical Oncology, Milan, Italy Purpose or Objective Recurrent or metastatic ACC (R/M ACC) might be managed by watchful waiting, reserving active treatment for progressing tumors. Lenvatinib, a potent anti-angiogenic agent, demonstrated a promising activity in two phase 2 studies, leading to its recommendation as first line treatment in the recent ASCO guidelines. Lenvatinib has been approved in Italy in July 2020 (law 648/1996). Our purpose was to evaluate the activity and toxicity of lenvatinib in R/M ACC patients 1 year after its approval in Italy. Materials and Methods This is a multicenter, retrospective study. Patients (pts) with ECOG PS ≤ 2, age ≥ 18 years and diagnosis of R/M ACC were eligible. Any prior lines of systemic therapies, except lenvatinib, were allowed and progression was not mandatory at study entry. Tumor characteristics, previous treatment (surgery, radiation therapy RT, systemic therapies ST), timing of treatments, initial dose, dose reduction and duration of lenvatinib, have been analyzed. Radiological response was assessed by RECIST 1.1 and treatment-related adverse events (TRAEs) were reported according to the CTCAE v5.0. Results From August 2020 to August 2021, 44 pts were included within 16 Italian sites. Female gender was prevalent (68%) with a median age of 56 years (range 35-83) at treatment initiation and 32% of pts ≥ 65 years. Major salivary glands were the most common primary site (55%). Forty-one pts (93%) received surgery alone (19%) or with RT (photons or heavy ions HI). HI were delivered in 10 pts: 6 received carbon ions (5) or protons (1) as post-operative treatment for R1/R2 disease; 4 pts with local relapse were re-irradiated with HI. Sixteen pts (36%) received ST, 2 out 16 (12%) received more than one line of treatment. Evaluable for response were 37 pts out of 44 (84%) while 3 pts were not evaluated at time of analyses or discontinued lenvatinib before radiological control because of toxicity, patient’s will and drug unrelated decline in clinical condition or